ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO207

Statewide Burden and Trend of Kidney Cancer in the United States, 1990-2021: A Benchmarking Secondary Analysis

Session Information

Category: Onconephrology

  • 1700 Onconephrology

Authors

  • Akbariansaravi, Abrisham, American University of Antigua, Coolidge, Antigua and Barbuda
  • Munnangi, Pragathi, N.R.I Medical College, Guntur, Andhra Pradesh, India
  • Katikala, Venkata Ramana, Konaseema Institute of Medical Sciences and Research Foundation Hospital, Amalapuram, Andhra Pradesh, India
  • Hara, Mankarn, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India
  • Desai, Hardik, Gujarat Adani Institute of Medical Science, Bhuj, Gujarat, India
Background

In 2020, national expenditures for kidney cancer (KC) care in the United States were reported at $9.4 billion. This study is the first to assess the state-wide burden of KC over the past three decades, which includes the challenging first two years of the COVID-19 pandemic that impacted cancer management.

Methods

Using the Global Burden of Disease 2021 methodology, we analyzed the incidence, prevalence, deaths, disability-adjusted life years (DALYs), and years lived with disability (YLDs) related to KC by age, sex, year, and location across the United States from 1990-2021.
Using the Global Burden of Disease 2021 methodology, we analyzed the incidence, prevalence, deaths, disability-adjusted life years (DALYs), and years lived with disability (YLDs) related to KC by age, sex, year, and location across the United States from 1990-2021.

Results

Over this period, the total percentage change (TPC) showed a 90% increase in KC prevalence (95% UI: 83-96%), a 61% rise in mortality (53-66%), and an 83% increase in YLDs (75-91%). The age-standardized incidence rate (ASIR) rose by 2%, and YLDs by 1%. Mississippi experienced the highest increase in ASIR by 26%, while Massachusetts saw a decrease of 27%. Regarding mortality rates, Mississippi saw an 11% increase, whereas the District of Columbia saw the greatest decrease at 38%. Among age groups, the highest number of deaths was observed in the 70-74 age group, totaling 2,863 (95% CI: 2,684-2,980), and the highest DALYs were recorded in the 65-69 age group, totaling 63,803 (95% CI: 60,635-66,470) in 2021. Males showed a higher burden compared to females, with a 3% increase in incidence rates, while females saw a 7% decrease from 1990-2021.

Conclusion

Kidney cancer accounted for 2.52% of all cancer-related deaths. These findings highlight the urgent need for focused efforts to manage the increasing burden of kidney cancer. Public health strategies should focus on improving early detection, optimizing treatment approaches, and ensuring widespread access to care to reduce the impact of this disease.